PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Stopped Study terminated based on internal business considerations and was not based on safety reasons

Conditions

• Advanced Solid Tumors
• Gastric Cancer
• Gastroesophageal Junction Cancer
• Urothelial Cancer
• Non Small Cell Lung Cancer
• Head and Neck Squamous Cell Carcinomas

Interventions

• DRUG: PF-07265028
• BIOLOGICAL: Sasanlimab

Sponsor

Pfizer